Customizing carrier screening in the Chinese population: Insights from a 334‐gene panel
Prenatal Diagnosis · 2024
DOI: 10.1002/pd.6635 ↗At a glance
Journal article in Prenatal Diagnosis, 2024. Written by Sha Liu and 11 co-authors. Institution: Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China. Major MEDLINE topics: East Asian People, Genetic Carrier Screening. Cited 12 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National 14th Five-Year key Research and Development Plan of China, National Key R&D Program of China, Science and Technology Department of Sichuan Province.
Abstract (original language)
Objective
This study aimed to evaluate the yield and applicability of expanded carrier screening and propose carrier rate screening thresholds suitable for the Chinese population by comparing the current screening panel with the American College of Medical Genetics and Genomics recommended panel of 113 genes.
Methods
Using targeted next‐generation sequencing, a customized panel with 334 genes was performed on 2168 individuals without clinical phenotypes for expanded carrier screening purpose. Variant interpretation followed the American College of Medical Genetics and Genomics guidelines. Carrier rates were calculated for each identified variant and each gene. At‐risk couple rates were also assessed. The yield of expanded carrier screening was evaluated through calculating cumulative carrier rate.
Results
Overall, 65.87% of the individuals were found to be carriers of at least 1 disease causing variants. The overall at‐risk couple rate was 11.76%, of which the GJB2 :c.109G > A related at‐risk couple rate was 5.78%. The cumulative carrier rate of 334‐panel was 65.53%. When screened genes with gene carrier rate ≥1/1000, the expanded carrier screening can cover over 90% of the cumulative carrier rate and at‐risk couples. A total of 86 genes overlapped with American College of Medical Genetics and Genomics Tier‐3 genes and were attributed to the cumulative carrier rate of 47.33%.
Conclusion
Expanded carrier screening using the 334‐gene panel showed high screening efficiency. A threshold of gene carrier rate ≥1/1000 is recommended for selecting carrier screening genes in the Chinese Han population. This study highlights the importance of customizing screening panels based on the ACMG Tier‐3 genes in conjunction with population‐specific carrier frequencies to improve the accuracy and effectiveness of expanded carrier screening.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.
- AmCare Genomics Lab, Guangzhou, China.
- Department of Reproductive Andrology/Human Sperm Bank, West China Second University Hospital, Sichuan University, Chengdu, China.
ORCID profiles: Sha Liu
Funding
- National 14th Five-Year key Research and Development Plan of China
- National Key R&D Program of China
- Science and Technology Department of Sichuan Province
- Science and Technology People-benift Project of Chengdu Science and Technology Bureau
Cite
APA
Liu, S., Huang, S., Zhang, V. W., Cao, L., Liu, H., Wei, X., Luo, Y., Li, Y., Zhou, L., Li, F., Zhu, Q., & Liu, H. (2024). Customizing carrier screening in the Chinese population: Insights from a 334‐gene panel. Prenatal Diagnosis. https://doi.org/10.1002/pd.6635
Vancouver
Liu S, Huang S, Zhang VW, Cao L, Liu H, Wei X, et al. Customizing carrier screening in the Chinese population: Insights from a 334‐gene panel. Prenatal Diagnosis. 2024. doi:10.1002/pd.6635
BibTeX
@article{Liu2024,
author = {Liu, Sha and Huang, Shuang and Zhang, Victor Wei and Cao, Liyuan and Liu, Haipeng and Wei, Xiang and Luo, Yuan and Li, Yue and Zhou, Lin and Li, Fuping and Zhu, Qian and Liu, Hongqian},
title = {Customizing carrier screening in the Chinese population: Insights from a 334‐gene panel},
journal = {Prenatal Diagnosis},
year = {2024},
doi = {10.1002/pd.6635}
}
EUVIMED